共 261 条
[11]
Ying R(1993)Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 363 458-460
[12]
Zhang X(2000)The RET proto-oncogene in human cancers Oncogene 19 5590-5597
[13]
Lodish MB(2005)The RET proto-oncogene: a molecular therapeutic target in thyroid cancer Cancer Sci 96 143-148
[14]
Stratakis CA(2002)ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 7284-7290
[15]
Carter MT(2013)Vandetanib for the treatment of medullary thyroid cancer Clin Cancer Res 19 524-529
[16]
Yome JL(2011)Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 2298-2308
[17]
Marcil MN(2012)Completing the Arc: targeted inhibition of RET in medullary thyroid cancer J Clin Oncol 30 200-202
[18]
Martin CA(2013)Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase Mol Cell Endocrinol 377 1-6
[19]
Vanhorne JB(2007)Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene J Am Chem Soc 129 10220-10228
[20]
Mulligan LM(1987)A long polypyrimidine/polypurine tract induces an altered DNA conformation on the 3′ coding region of the adjacent myosin heavy chain gene Nucleic Acids Res 15 8069-8085